Impact of the Synbiotics and Urate-Lowering Therapy on Gut Microbiota and Cytokine Profile in Patients with Chronic Gouty Arthritis
| Autor: | Oksana Mykhailivna Tarasenko, Olena Myroslavivna Karmazina, Valentyn Valentinovich Taranchuk, V Kondratiuk |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Gout Synbiotics Cytokine profile medicine.medical_treatment Interleukin-1beta Gut flora Gastroenterology 0302 clinical medicine synbiotic TNF - tumor necrosis factor biology Arthritis Gouty MSU - monosodium urate General Medicine Middle Aged C-Reactive Protein Cytokine Female Original Article Tumor necrosis factor alpha medicine.symptom medicine.drug medicine.medical_specialty BOS - bacterial overgrowth syndrome Allopurinol HU-hyperuricemia Inflammation ULT - urate-lowering therapy Bacteria Anaerobic 03 medical and health sciences Internal medicine medicine Humans 030203 arthritis & rheumatology therapy fecal microbiota Tumor Necrosis Factor-alpha UA - uric acid business.industry medicine.disease biology.organism_classification cytokines CFU - colony-forming unit Gastrointestinal Microbiome Uric Acid 030104 developmental biology GIT - gastrointestinal tract Chronic Disease NSAIDs - non-steroidal anti-inflammatory drugs business IL - interleukin |
| Zdroj: | Journal of Medicine and Life |
| ISSN: | 1844-3117 1844-122X |
| DOI: | 10.25122/jml-2020-0065 |
| Popis: | The main goal of our study is the impact evaluation of complex urate-lowering therapy with the synbiotic addition on fecal microbiota and cytokine profile in patients with primary gout. During our study, 130 men (mean age 55.5 ± 9.4 years) with gout (duration 7.7 ± 7.1 years) were examined. All patients were divided into two treatment groups. The main group (n = 68) was taking allopurinol at 300 mg per day dose and additionally a synbiotic. The comparison group (n = 62) received allopurinol monotherapy without synbiotic intake. The therapy duration was 3 months. Evaluation of therapy efficiency was marked by blood uric acid changes, cytokine levels, CRP and fecal microbiota condition. After treatment, stabilization of the gut microbiota parameters was observed, which was leading to normalization uricemia levels (40.3% vs. 21%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|